Contraceptive Effect of Sperm-Agglutinating Monoclonal Antibodies in Rabbits1

Castle, Philip E.; Whaley, Kevin J.; Hoen, Timothy E.; Moench, Thomas R.; Cone, Richard A.

doi:10.1095/biolreprod56.1.153

Cited by 41 publications

(29 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, an anti-rabbit sperm mAb has been shown to provide contraceptive activity in a rabbit model. 32 A mAb (HC4) against a surface glycolipid present on human sperm has been produced in the ΔXF Nicotiana line and shown to co-agglutinate 100% of sperm and other seminal cells in less than thirty seconds at 100 ug/ml (Fig. 2).…”

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning

confidence: 99%

Emerging antibody products and Nicotiana manufacturing

2011

Self Cite

View full text Add to dashboard Cite

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning

confidence: 99%

Emerging antibody products and Nicotiana manufacturing

2011

Self Cite

View full text Add to dashboard Cite

“…This may closely mimic the normal function of antibodies in the mucosal immune system, e.g., antibodies in breast milk help protect the surfaces of the mouth, nose, eyes, and digestive tract of the baby. To date, the results of studies performed indicate that monoclonal antibodies delivered to the vagina may help prevent pregnancy as well as sexual transmission of genital herpes and HIV (161)(162)(163)(164).…”

Section: Monoclonal Antibodies As Microbicidesmentioning

confidence: 99%

A Review of Current Intravaginal Drug Delivery Approaches Employed for the Prophylaxis of HIV/AIDS and Prevention of Sexually Transmitted Infections

et al. 2008

View full text Add to dashboard Cite

Abstract. The objective of this review is to describe the current status of several intravaginal anti-HIV microbicidal delivery systems these delivery systems and microbicidal compounds in the context of their stage within clinical trials and their potential cervicovaginal defence successes. The global Human Immuno-Deficiency Virus (HIV) pandemic continues to spread at a rate of more than 15,000 new infections daily and sexually transmitted infections (STIs) can predispose people to acquiring HIV infection. Male-to-female transmission is eight times more likely to occur than female-to-male transmission due to the anatomical structure of the vagina as well as socio-economic factors and the disempowerment of women that renders them unable to refuse unsafe sexual practices in some communities. The increased incidence of HIV in women has identified the urgent need for efficacious and safe intravaginal delivery of anti-HIV agents that can be used and controlled by women. To meet this challenge, several intravaginal anti-HIV microbicidal delivery systems are in the process of been developed. The outcomes of three main categories are discussed in this review: namely, dual-function polymeric systems, non-polymeric systems and nanotechnology-based systems. These delivery systems include formulations that modify the genital environment (e.g. polyacrylic acid gels and lactobacillus gels), surfactants (e.g. sodium lauryl sulfate), polyanionic therapeutic polymers (e.g. carageenan and carbomer/lactic acid gels), proteins (e.g. cyanovirin-N, monoclonal antibodies and thromspondin-1 peptides), protease inhibitors and other molecules (e.g. dendrimer based-gels and the molecular condom). Intravaginal microbicide delivery systems are providing a new option for preventing the transmission of STIs and HIV.

show abstract

“…Agglutination of rabbit sperm with unformulated IgM Ab has been shown to provide contraceptive activity in a rabbit model (Castle et al, 1997); this study mimics the agglutination mechanism that is associated with immune infertility in humans (WHO, 1992). A Nicotiana manufactured IgG 1 against a unique (found only in the human male reproductive tract) glycoform of CD52, i.e.…”

Section: Topical Antibodiesmentioning

confidence: 95%

Antibody-based concepts for multipurpose prevention technologies

Whaley

Zeitlin

2013

Antiviral Research

Self Cite

View full text Add to dashboard Cite

Because of the versatility and specificity of monoclonal antibodies, they are candidates for multipurpose prevention technologies when formulated as topical (gels, films, rings) or injectable drugs and as vaccines. This review focuses on antibody-based proof of concept studies for the human immunodeficiency virus, herpes simplex virus and sperm. Opportunities and challenges in antibody evasion/resistance, manufacturing, regulatory, and pharmacoeconomics are discussed. This article is based on a presentation at the “Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies,” held in Arlington, Virginia on February 21-22, 2013. It forms part of a special supplement to Antiviral Research.

show abstract

Contraceptive Effect of Sperm-Agglutinating Monoclonal Antibodies in Rabbits1

Cited by 41 publications

References 33 publications

Emerging antibody products and Nicotiana manufacturing

Emerging antibody products and Nicotiana manufacturing

A Review of Current Intravaginal Drug Delivery Approaches Employed for the Prophylaxis of HIV/AIDS and Prevention of Sexually Transmitted Infections

Antibody-based concepts for multipurpose prevention technologies

Contact Info

Product

Resources

About